FORT LAUDERDALE, Fla., Feb. 11, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced the signing of a five year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
TrialMaster was selected after an exhaustive evaluation that included OmniComm and six other leading EDC solution providers to select the replacement for their legacy EDC application. Specific evaluation emphasis was placed on fast study build time, ease of data extraction in submission ready data format, direct patient data entry and a comprehensive feature set. TrialMaster was found superior in all categories when compared to the other six competing EDC technologies. The depth and breadth of functionality, ease of contracting, and a highly responsive executive management team were significant factors in the selection of TrialMaster EDC.
Trial build time was of particular interest as this clinical development team will be responsible for building their own studies. They found TrialMaster’s rich and versatile design and build toolset easier to learn and easier to work with when compared to the competing technologies and thereby enabling faster study build times. TrialMaster will be deployed within OmniComm’s OmniCloud® for hosting and maintenance of the entire IT infrastructure, ensuring clinical data management technology is always running; data is secure, and product enhancements are rolled out seamlessly.
“We are very pleased that, across a field of highly regarded EDC technologies, OmniComm’s TrialMaster was selected as the best solution by a very knowledgeable and savvy group of clinical professionals,” states Kuno van der Post, SVP of business development, OmniComm. “We are all extremely excited to see this new client showcase our software.”
Supporting Information
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, OmniCloud, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
OmniComm Systems, Inc. 2101 West Commercial Blvd. Suite 3500 Fort Lauderdale, FL 33309 USA Phone: +1.954.473.1254 Fax: +1.954.473.1256 www.omnicomm.com


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Italy Fines Apple €98.6 Million Over App Store Dominance
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



